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Abstract
Background: Despite sharing 92% sequence identity, paralogous human translation elongation factor 1 alpha-1 (eEF1A1)
and elongation factor 1 alpha-2 (eEF1A2) have different but overlapping functional profiles. This may reflect the differential
requirements of the cell-types in which they are expressed and is consistent with complex roles for these proteins that
extend beyond delivery of tRNA to the ribosome.
Methodology/Principal Findings: To investigate the structural basis of these functional differences, we created and
validated comparative three-dimensional (3-D) models of eEF1A1 and eEF1A2 on the basis of the crystal structure of
homologous eEF1A from yeast. The spatial location of amino acid residues that vary between the two proteins was thereby
pinpointed, and their surface electrostatic and lipophilic properties were compared. None of the variations amongst buried
amino acid residues are judged likely to have a major structural effect on the protein fold, or to affect domain-domain
interactions. Nearly all the variant surface-exposed amino acid residues lie on one face of the protein, in two proximal but
distinct sub-clusters. The result of previously performed mutagenesis in yeast may be interpreted as confirming the
importance of one of these clusters in actin-bundling and filament disorganization. Interestingly, some variant residues lie in
close proximity to, and in a few cases show differences in interactions with, residues previously inferred to be directly
involved in binding GTP/GDP, eEF1Ba and aminoacyl-tRNA. Additional sequence-based predictions, in conjunction with the
3-D models, reveal likely differences in phosphorylation sites that could reconcile some of the functional differences
between the two proteins.
Conclusions: The revelation and putative functional assignment of two distinct sub-clusters on the surface of the protein
models should enable rational site-directed mutagenesis, including homologous reverse-substitution experiments, to map
surface binding patches onto these proteins. The predicted variant-specific phosphorylation sites also provide a basis for
experimental verification by mutagenesis. The models provide a structural framework for interpretation of the resulting
functional analysis.
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Introduction
Translation elongation factor alpha (eEF1A) has a pivotal role
in protein synthesis, since it is responsible for delivering
aminoacylated tRNAs to the A site of the ribosome. In higher
vertebrates, eEF1A is found in two variant forms, encoded by
distinct genes [1], and with different expression patterns. The
near-ubiquitous form, eEF1A1, is expressed in all tissues
throughout development but is absent in adult muscle and heart
[2,3]. The latter tissues express instead eEF1A2 as do certain other
cell types including, notably, large motor neurons, islet cells in the
pancreas and enteroendocrine cells in the gut [4].
Despite sharing 92% sequence identity (Figure 1), paralogous
human eEF1A1 and eEF1A2 have different functional profiles. They
exhibit similar translation activities, but have different relative
affinities for GTP and GDP [5]. eEF1A1 binds GTP more strongly
than GDP, whereas the opposite is the case for eEF1A2. The GDP
dissociation rate constant is seven-fold higher for eEF1A1 than for
eEF1A2, and the GDP/GTP preference ratio is 0.82 for eEF1A1, but
1.50 for eEF1A2. Surprisingly, since this would predict its greater
reliance on GTP-exchange factors, eEF1A2 appears to show little or
no affinity for the components of the guanine-nucleotide exchange
factor (GEF) complex eEF1B in yeast-two-hybrid experiments [6].
eEF1B is made up of three subunits, eEF1Ba,e E F 1 B D (called
eEF1Bb in plants) and eEF2Bc [7]. The eEF1Ba and eEF1BD
subunits possess guanine nucleotide-exchange activity, whereas the
eEF2Bc subunit is thought to have a more structural role, tethering
the complex to the membrane of the endoplasmic reticulum.
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6315Figure 1. Sequence alignment between human eEF1A1 and eEF1A2 and yeast template. The pair-wise sequence alignment between
human eEF1A1 and eEF1A2 is shown: identical residues (yellow background), variant residues (red background). The aligned yeast eEF1A template is
shown below with identical residues to the human sequences highlighted (yellow background) and any variant position between yeast and either
human sequence shown with a white background. The two human sequences share 92% sequence identity with each other and each show ,81%
sequence identity with the yeast protein. The domain boundaries (domain I: cyan; domain II: green; domain III: pink), and STRIDE [44] secondary
structure assignment is traced above the yeast template sequence (arrows=beta-strands; coils=alpha-helices). The amino acid residues involved in
domain-domain contacts are indicated with a brown circle (green circle for non-identical equivalent residues between two human variants); those
involved in the binding of C-terminal fragment eEF1Ba are indicated on the yeast sequence with blue rectangles; residues involved in GDP-binding
indicated in pink rectangles; and those disordered in the yeast crystal structure are indicated with a dashed rectangle. Yeast mutagenesis data and
motifs are highlighted on its sequence: mutations involved in actin bundling/disorganization (red rectangles) [70,71]; mutations that affect
translational fidelity (green rectangles) [77]; mutations that reduce dependence on eEF1B (orange rectangles) [78,79].
doi:10.1371/journal.pone.0006315.g001
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functions (reviewed in [8]), including actin-binding and bundling
[9], apoptosis [10], nuclear transport [11], proteasomal-mediated
degradation of damaged proteins [12], heat shock [13] and
transformation [14]. eEF1A2 has been less extensively studied at
the biochemical level, so it is not yet clear how many of these non-
canonical functions are shared by this variant. For example,
eEF1A2 has been shown to have a role in actin remodeling in cells
[15], but has not been shown directly to bind to actin. In humans,
eEF1A2 has been shown to have oncogenic properties when
inappropriately overexpressed, and has been implicated in
ovarian, breast, pancreatic, liver and lung cancer
[16,17,18,19,20], although the mechanism for overexpression
remains elusive, and no mutations have been identified in ovarian
tumors [21]. Loss of expression of eEF1A2, on the other hand, has
been shown in mice to result in motor neuron degeneration
reminiscent of motor neuron disease, or amyotrophic lateral
sclerosis [3,22,23].
There appears to be a complex interplay between eEF1A and its
binding partners that has the net effect of balancing its canonical
activity in peptide synthesis with its non-canonical actin-binding
and bundling functions. Such a balance may be critical for an as
yet little-understood integration of gene expression and cytoskel-
etal dynamics. In higher eukaryotes, different cell types are likely
to have different requirements in terms of both protein synthetic
capacity and cytoskeletal regulation. It is possible that competition
for binding between aminoacyl-tRNA and actin may tilt the
balance between the two functions. The presence of the two
variants in mammals creates the potential for greater complexity
than is seen in yeast: whilst Saccharomyces cerevisiae has two genes
encoding eEF1A and Schizosaccharomyces pombe has three, the
encoded proteins are identical within a given species [24,25]. One
hypothesis is that the two mammalian variants eEF1A1 and
eEF1A2 differ in the extent to which they participate in peptide
synthesis versus actin bundling, and that this lies behind their
differential expression in various cell types. For example, motor
neurons express eEF1A2 and not eEF1A1 [4]; these cells can
reach up to a meter in length in humans, and it is tempting to
speculate that their cytoskeletal organization would have different
constraints from those of, say, hepatocytes. This hypothesis
predicts that there will be differences in binding affinities or
specificities for aminoacyl-tRNA and/or actin mediated by
differences in the amino acid residues that comprise the respective
binding sites.
From the pair-wise sequence alignment between the two human
variants (Figure 1), it is apparent that many of the changes involve
substitution of Ser or Thr (total of 11); although no Tyr amino acid
residues are lost or gained. This observation leads to a second
hypothesis; that differential phosphorylation of the two variants
effectively amplifies their chemical differences and promotes
functional divergence. It is well known that all four subunits (i.e.
one monomeric eEF1A subunit and three eEF1B subunits) of the
assembled ‘heavy’ elongation factor complex are targets for
kinases. Large-scale proteomics studies revealed that conserved
Tyr residues (Tyr29, Tyr85, Tyr86, Tyr141, Tyr162, Tyr254) in
both human eEF1A variants [26,27,28,29] are phosphorylated. In
most studies, it is impossible to judge whether peptides variously
identified as originating from eEF1A1 or eEF1A2 are actually
specific to one variant, as the peptides identified are from regions
that are completely conserved between eEF1A1 and eEF1A2.
Rikova et al. [27] identify eEF1A2 as a substrate for anaplastic
lymphoma kinase in lung cancer patients. This is consistent with
expression data as this variant is overexpressed in lung
adenocarcinoma cell lines [20] while the EEF1A2 gene is amplified
in lung cancer cell lines [30]. Furthermore, we have shown that
whilst eEF1A2 is overexpressed in a significant subset of primary
lung tumors, eEF1A1 expression remains constant when com-
pared with normal lung tissue (J.Boyd, W.Wallace and C.Abbott,
unpublished data). On the other hand, Molina et al. [28], in a
study of phosphopeptides in human embryonic kidney cells,
identified phosphorylation of, unequivocally, eEF1A1 at Tyr29
and Ser163. Rush et al. [26] identified a number of tyrosine
phosphorylation sites in eEF1A from various cell lines, but in each
case the phosphorylated peptides are from completely conserved
regions and thus could have originated from either variant.
Additional confirmation of tyrosine phosphorylation was presented
by Panasyuk et al. [31] who proposed that while both variants
could be involved in phosphotyrosine-mediated processes, eEF1A2
had greater potential to participate in such signaling pathways.
Lamberti et al. confirmed serine and threonine phosphorylation of
eEF1A, and suggested other likely Ser and Thr phosphorylation
sites based on a bioinformatics study of eEF1A1 [32]. However all
of their predicted sites (Ser18, Ser157, Ser316, Ser383, Thr242
and Thr432) are conserved between the two variants and their
study did not distinguish between the two variant forms. In
agreement with one of the abovementioned phosphorylation
predictions, Eckhardt et al. confirmed phosphorylation of Thr432
in eEF1A1 via mass spectrometry and site-directed mutagenesis
[33]. Thus the hypothesis that non-conserved Thr and Ser
residues of eEF1A1 and eEF1A2 are targets for phosphorylation
remains untested. One way to begin investigating this hypothesis is
to adopt a structural approach (in conjunction with sequence-
based phosphorylation predictors) and to examine whether the
residues in question are exposed and accessible to kinases or
buried and inaccessible.
To date there have been no published mutagenesis reports
specifically aimed at delineating binding sites in the human
eEF1A variants but there are mutagenesis data, and several three-
dimensional (3-D) structures, for yeast eEF1A. We therefore set
out to construct and validate 3-D models of human eEF1A1 and
eEF1A2 on the basis of homology with a known structure of yeast
eEF1A. Modeling by homology is a well-established technique,
and protein models have wide-ranging applications in biomedical
research (see [34] for recent review). The plan was to examine the
locations in the structure of the non-conserved residues, to assess
the extent to which these are exposed (in the case of Ser or Thr)
for possible phosphorylation, or occupy putative ligand and
protein-binding sites, and thereby to test the aforementioned
hypotheses.
Methods
Target sequences, template identification and selection
The target sequences used were eEF1A1 [residues 1-443 (out of
462); SwissProt Accession No: P68104] and eEF1A2 [residues 1-
443 (out of 463); SwissProt Accession No: Q05639]. A BLAST
search [35] for each of the target sequences against the Protein
Data Bank (PDB) [36] returned six highly similar potential
templates [PDB IDs: 1F60, 1G7C, 1IJE, 1IJF, 2B7B, 2B7C] from
Saccharomyces cerevisiae [37,38,39] with an E-value of 0.0 (sequence
identity ,81%). All these structures were solved in complex with
the C-terminal eEF1Ba fragment and in some cases with GDP,
GDPNP, or GDP-Mg
2+ bound. Upon superposition, the structural
arrangements/orientations for the three domains are almost
identical (Ca RMSD: 0.1 to 0.7 A ˚) among the six structures
(Supplementary file S1). The highest resolved structure from this
set – the 1.67-A ˚ X-ray-derived eEF1A protein structure from yeast
[38] (PDB ID: 1F60, chain A) was selected as the template.
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Optimal template selection, and target-to-template alignment is
key to the success of any modeling exercise [40,41]. The alignment
between the targets and template sequences (Figure 1) for
modeling purposes, was based on a multiple-sequence alignment
among them using the program ClustalX [42]. Because of their
high sequence similarity, the alignment was predictably trivial, and
no further manual editing was required. The targets eEF1A1 and
eEF1A2 share 81% and 80% sequence identity (,89% similarity)
respectively with the template (Figure 1). Unsurprisingly,
PSIPRED v2.5 [43] predicted near-identical secondary structure
for both variants (not shown). The STRIDE [44] identified
secondary structure for the template when overlaid on the
sequence alignment, showed that the two gaps were indeed placed
within a loop region (Figure 1).
Model building and refinement
The two target-template alignments were individually used as
inputs for the program Modeller release 8 version 2 [45]. Twenty
models were generated and, in each case, the ones with the lowest
value of the objective function score were selected as the representative
models. Non-identical side-chain residues for each representative
model were optimized using the side-chain replacement program,
SCWRL version 3 [46,47]. The models were then protonated
under SYBYL version 6.9 (Tripos Associates, St. Louis, MO,
USA), and subject to brief energy minimization (20 steps steepest
descent, followed by 20 steps conjugate gradients) employing the
Tripos forcefield [48] under SYBYL v6.9 to remove clashes and
bad geometries.
Model evaluation
The models were checked for valid stereochemistry (Supple-
mentary file S2) using PROCHECK version 3.5.4 [49]. The
coarse packing quality of the models was assessed using the
WHAT IF server (http://swift.cmbi.ru.nl/servers/html/index.
html) [50,51], and the models additionally evaluated using the
MetaMQAP II server (https://genesilico.pl/toolkit/unimod?-
method=MetaMQAPII) [52]. The final models are available for
download (Supplementary file S3).
Analysis of model properties
PyMol (http://www.pymol.org; DeLano Scientific, San Carlos,
CA, USA) was used for structurevisualization. Yeast eEF1A-eEF1Ba
interacting amino acid residues and eEF1A domain-domain contacts
(Figure 1) were identified using the Protein Interactions Calculator
(PIC) [53]. PIC identifies all hydrophobic interactions within 5 A ˚,
main-chain to main-chain, main-chain to side-chain and side-chain
to side-chain hydrogen bonds, ionic interactions, aromatic-aromatic
interactions, aromatic-sulfur interactions, and cation-pi interactions.
Proximity of putative binding site residues with respect to variant
amino acid residues was identified by using a 5 A ˚ sphere radius from
the binding site amino acid residues under PyMol. Structural
superpositions were undertaken using MultiProt (http://bioinfo3d.cs.
tau.ac.il/MultiProt/) [54]. Solvent-accessibility calculations were
performed using GETAREA version 1.1 (http://curie.utmb.edu/
getarea.html) using a sphere probe radius of 1.4 A ˚ [55]. Electrostatic
surface representations were generated using GRASP [56] and
lipophilic surface renditions created using MOLCAD [57] under
SYBYL v6.9.
Phosphorylation prediction
The human eEF1A1 and eEF1A2 amino acid sequences were
used to search the translated nucleotide database ‘nr/nt’ at NCBI
using BLAST (tblastn) (http://www.ncbi.nlm.nih.gov/blast/Blast.
cgi) [35]. The retrieved orthologues were then used as input to
ClustalX for multiple sequence alignment. BOXSHADE was used
for shading sequence conservation. Phosphorylation site prediction
was performed using the NetPhos version 2 server (http://www.
cbs.dtu.dk/services/NetPhos/) [58] and mapped onto the align-
ment and 3-D model.
Results and Discussion
Quality assessment of the 3-D models of human eEF1A1
and eEF1A2
Themodels ofeEF1A1 andeEF1A2 were created based upon the
yeast crystal structure of eEF1A and evaluated for stereochemistry,
packing quality and expected accuracy. The Ramachandran
dihedral statistics [49,59] for both models were good; eEF1A1:
93.6% most favored, 5.1% additionally allowed, 1.1% generously
allowed, 0.3% disallowed; and eEF1A2: 92% most favored, 6.7%
additionally allowed, 1.3% generously allowed, 0% disallowed.
Additionally, the packing quality [50,51] for the models attained
overallaverage qualitycontrolscoresof 20.89 (eEF1A1) and 20.87
(eEF1A2). To place this in context, incorrect models give scores
of,23.0; lower quality models,22.0; and the average quality of
200 highly refined X-ray structures 20.5 (+or 20.4). The absolute
global deviations, expressed as Root Mean Square Deviation
(RMSD) and Global Distance Test Total Score (GDT_TS [60]) by
MetaMQAP II [52] for the models versus the unknown true
structures were sound (eEF1A1: GDT_TS: 80.3, RMSD: 1.9 A ˚ and
eEF1A2: GDT_TS: 78.5; RMSD: 2.0 A ˚), indicating high quality
models. Theseevaluationstatisticsareinline with thehigh sequence
identity (,81%) and similarity (89%) of the targets to the eukaryotic
yeast template, the presence of only two gaps in the target-template
alignment (Figure 1), and the high-resolution quality of the
determinedtemplatecrystalstructure(1.67 A ˚)[38].Takentogether,
the result is that the quality of the models created approaches that of
experimentally determined structures [40].
Another, albeit less similar template from the archaeon,
Sulfolobus solfataricus [61,62] (,53% sequence identity) was also
detected from the BLAST search [35] against the PDB [36] and
has been used as a template in previous modeling studies for the
human variants [32,63]. This template was not included in our
modeling protocol because of its significantly lower sequence
similarity, and larger number of gaps (3%) when compared with
the yeast template. Moreover, comparison of the secondary
structure of this potential template (PDB ID: 1JNY chain A) with
the eukaryotic yeast template (PDB ID: 1F60 chain A) reveals
differences – for example, two beta-strands at positions 212–223 in
yeast that encompass two variant amino acid residues in humans,
are absent in archaea; the loop after the third alpha-helix in
domain I in the archaeal structures [61,62] contain eleven residues
(Arg66-Phe76) that are disordered - five of these residues are
directly involved in eEF1Ba-binding. This would translate into a
dearth of distance restraints for that region for modeling purposes.
Additionally, the orientation of two helices and the switch 1 region
are different [61,62]. Finally, while their individual domains
overlay reasonably well (Ca RMSD: 1 to 1.9 A ˚), the relative
orientation of domain I with respect to domains II and III in yeast
and archaea is different [62]. This may or may not be attributable
to the structural rearrangements that accompany eEF1Ba-binding
in the yeast structure, since the domain-domain orientations
adopted by a ligand-free yeast eEF1A, is at yet unknown.
Nonetheless, given the abovementioned limitations of using the
archaeal template, it is prudent to adopt the ligand-bound eEF1A
yeast template, singularly, for modeling other eukaryotic targets.
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Structurally, each model (like the template) consists of three
domains, referred to as domain I, domain II and domain III
(Figure 2). Domain I (residues 1-to-240) is made up of a
Rossmann-fold topology. Domains II (residues 241-to-336) and
III (residues 337-to-443) are made up almost entirely from beta-
strands; each domain contains two beta-sheets that form a beta-
barrel.
The 32 out of 36 variations in amino acid residues between the
two human proteins are distributed over all three domains
(Figures 1 and 2). The remaining four variations were not
modeled because they are present within a disordered region at the
C-terminus of the yeast template, and hence it is unknown how
they may influence the overall structure or binding-interactions.
Only six (out of 32) amino acid residues that are variable between
the two human proteins are completely buried in the modeled
structures. Two of these are conservative changes (Val87Ile and
Leu361Ile) while two others entail substitution of an alanine for
another small residue (Ala326Cys and Ala342Ser); the remaining
pair of substitutions (Pro161Ala, Ala189Pro), while not so
obviously conservative, can readily be accommodated within the
protein core as judged from their excellent packing scores. Thus
there is nothing to suggest that individual domain structures will
differ between the two human variants.
A total of 40 out of 42 residues involved in domain-domain
contacts amongst the three domains are identical (Figure 1) for the
two variants and the yeast template (contacts identified using PIC
[53]). The exceptions are Met/Gln335Lys (residue in linker
connecting domains II and III) and Asp/Gln417Glu (domain III)
in human eEF1A1/eEF1A2, versus yeast eEF1A. The side-chains
of these amino acid residues are, however, largely surface-exposed
(Figure 3) and they retain their inter-domain H-bonds (from their
main-chain oxygen atoms to the side-chains of Cys409 and
Lys242, respectively). This excellent conservation of inter-domain
interfaces reinforces the inference from the very high quality of the
homology-based models that both human variants may adopt the
same conformation as observed in the eEF1Ba-complexed
structure of yeast eEF1A. These observations do not shed light
on the issue of whether or not domain rearrangements accompany
association or disassociation of eEF1B. It is noteworthy that of the
42 residues involved in domain-domain contacts within the
eEF1Ba-bound yeast structure, 17 are not absolutely conserved
in the archaeal Sulfolobus solfataricus sequence; likewise, of the 40
residues involved in domain-domain contacts within the unbound
archaeal structure, 14 are not absolutely conserved in the yeast
sequence (Supplementary file S4). This observation is consistent
with the notion that the domain arrangement within the archaeal
EF1A structure is not necessarily mirrored in the eEF1B-free forms
of human eEF1A, and reinforces our decision to model human
eEF1A1 and eEF1A2 on the yeast template.
Surface-exposed variant amino acids between the two
proteins lie in sub-clusters located on one-side of the
protein
Mapping the variable residues on the model surfaces (middle
and bottom panel, Figure 3) reveals that almost all of them
congregate on one face of the molecule – on the opposite face from
the C-terminal eEF1Ba-binding site (top panel, Figure 3) as
proposed in [6] on the basis of the yeast crystal structure. These
non-conserved residues are located in two distinct sub-clusters on
the same face, but separated by a distance of ,27 A ˚ (measured
between residues 220 and 417); a circular band of residues lying
within domain I (cluster 1, 12 residues, ,35 A ˚ in diameter), and a
swathe of residues spread across domains II and III (cluster 2, 14
residues, ,46612 A ˚). It seems highly unlikely that such clustering
would occur by chance and it is therefore reasonable to infer that
the clusters correspond to binding sites for one or more partners.
Such an inference is reinforced by multiple- sequence alignments
with eukaryotic orthologues in which it is apparent that the
residues contributing to these clusters are very highly conserved
within their respective eEF1A1 and eEF1A2 families (Figure 4).
Other models for eEF1A1 have been created previously.
Lamberti et al. [32] created a homology model of the eEF1A1
variant, based on Sulfolobus solfataricus EF1A, which is probably a
less suitable template than yeast eEF1A for several reasons
discussed previously. Marco et al. [64] used a model based on the
yeast eEF1A template to assess the ability of a potent inhibitor of
protein synthesis (didemnin B) to bind human eEF1A1. Neither of
these studies extended to human eEF1A2. The only comparative
study between eEF1A1 and eEF1A2 to date was performed by
Kanibolotsky et al. [63] who reported near-identical modeled
structures and speculated on differences in the conformational
dynamics of the two variants, but did not highlight the sub-
clustering of variable amino acid residues that is a striking feature
of the current models. The ligands for these putative binding sites,
and any consequent differences in binding specificities of eEF1A1
versus eEF1A2, are a matter of speculation.
Comparison of electrostatic and lipophilic surface
properties
A closer inspection of surface properties of the modeled
structures should help understand how variations in sequence
mediate functional differences between eEF1A1 and eEF1A2.
Although virtually all the variable residues appear as two sub-
clusters on one face of the molecule (Figure 3), this face has similar
overall electrostatic and lipophilic characteristics in both molecules
(Figure 5). This is consistent with the fact that conservative
substitutions of residues account for three-quarters of the variation
between the two proteins (Figure 1). Individual conservative
changes likely alter functional properties only to a small degree.
But the combined effects on molecular recognition of numerous
conservative variations congregated in a surface patch could be
more dramatic. To this may be added the influence of the few
non-conservative variations; for example, the eEF1A2 variant (in
comparison with eEF1A1) has replaced neutral polar residues with
electronegative residues at positions Glu164 and Glu217, while
negative residues are substituted with Ala186 and Gln417 (in
cluster 1); the replacement of Phe393 (in eEF1A1) with Ser393 (in
eEF1A2) is a particularly notable substitution (in cluster 2).
Analysis of variant amino acid residues with respect to
putative protein/ligand binding sites
(a) eEF1Ba. The yeast eEF1A structure used as a template in
the current study was solved in complex with a fragment of
eEF1Ba [38]. Complex formation between yeast eEF1A and
eEF1Ba (fragment) (Figure 2) buries ,3558 A ˚ 2 of surface area
[38]. The binding site on eEF1A for the eEF1Ba C-terminal
fragment lies mainly on domains I and II, with only a single
contact with domain III (Arg428) [38]. A total of 24 out of 26
eEF1A residues that form the binding site for eEF1Ba, including
all eight residues that participate in salt-bridge formation, are
invariant in yeast and both human proteins (Figure 1). Two
interface residues, Ala76 and Val89 in yeast, are substituted in
both human proteins by similarly sized residues, Ser76 and Ile89,
respectively. Thus there are no differences between the two human
3D-Models of eEF1A1 and eEF1A2
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only variant (between eEF1A1 and eEF1A2) amino acid residue
within proximity of the eEF1Ba-binding site is Val/Ile320 that lies
within 5 A ˚ of three interface residues - Asp252, Val253 and
Arg322. Val320 (eEF1A1) and Ile320 (eEF1A2) are involved in a
hydrophobic interaction with Val253. Hence we may conclude
that all three proteins engage with eEF1Ba C-terminal fragment in
the same way and are likely to have similar affinities, despite yeast-
two-hybrid studies that failed to demonstrate an eEF1A2-eEF1B
interaction [6]. Mansilla et al suggest that there may be brain-
specific variants of eEF1Ba, and although one has been described
in human [65], we have shown that this appears to result from
expression of a processed pseudogene with no orthologue in mice
and is thus unlikely to be of functional significance [66]. However,
a further yeast-two-hybrid screen using mouse eEF1A2 as bait for
a mouse brain cDNA library also failed to pull out any eEF1B
Figure 2. Yeast template, human eEF1A1 and eEF1A2 models. Two views rotated by 180u about the y-axis depicting cartoon schematic
representations of: the yeast eEF1A (yellow)-eEF1Ba C-terminal fragment (magenta) crystal structure (top panel). The 3-D models of eEF1A1 (blue,
middle panel), and eEF1A2 (red, lower panel) show the location of variant side-chains (in stick representation) between the two proteins, colored
green. Secondary structure elements have been assigned by default settings in PyMol (http://www.pymol.org) and position of domains labeled.
doi:10.1371/journal.pone.0006315.g002
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results is that the N-terminal segment of eEF1Ba (.100 amino
acid residues) - which was not present in the yeast crystal structure
- wraps around and contacts the ‘‘far-side’’ of eEF1A1 [6],
stabilized by direct contacts at these sites of variation. Moreover, it
is known that eEF1A1 also interacts with eEF1BD [6]; eEF1BD
shows sequence similarity to eEF1Ba, and can also function as a
GEF [7]. Clearly, further experiments assessing binding between
Figure 3. Location of variations in amino acids mapped onto surface. Two equivalent views rotated by 180u about the y-axis depicting a
surface rendition of the yeast eEF1A crystal structure colored magenta (top panel), and the 3-D models of eEF1A1 colored blue (middle panel) and
eEF1A2 colored red (bottom panel). Locations of exposed variant side-chains are mapped onto the surface of the two model proteins (colored green)
and labeled on the eEF1A2 model - the variant residue from eEF1A1 is shown on the right-hand side of the label. The two sub-clusters are apparent in
this representation. The location of the C-terminal eEF1Ba-binding site (cyan) [38] and GDP-binding site (yellow) [39] is mapped on the crystal
structure. Also highlighted (red) on its surface are: mutations that reduce actin disorganization induced by overexpression of eEF1A, inhibit actin-
bundling without altering translation in vivo, and reduce actin-bundling [70,71]. There are no variants in proximity to those residues implicated on the
basis of mutagenesis to be involved in translational fidelity (green) [77]. However, two variant positions in humans - Gln164Glu and Glu168Asp are in
close proximity to Arg166 – a conservative mutation for the equivalent residue in yeast (Arg164Lys) was shown to reduce dependence on eEF1B
(orange) [78,79]. Gln164Glu and Glu168Asp, however, both retain their main-chain to main-chain H-bonds with Arg166. Note: for clarity the three
proposed aminoacyl-tRNA-binding residues [38] are not shown, since they overlap with already highlighted positions implicated in binding eEF1Ba
(His293 and Arg320) and actin (His294).
doi:10.1371/journal.pone.0006315.g003
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PLoS ONE | www.plosone.org 7 July 2009 | Volume 4 | Issue 7 | e6315Figure 4. Multiple sequence alignment of eEF1A1 and eEF1A2 orthologues. ClustalX alignment of eEF1A1 and eEF1A2 sequences from a
range of higher order eukaryotes. The results are shaded using BOXSHADE v3.21 (black background=strictly conserved; grey or white
background=conservatively substituted or non-conserved). A star-symbol denotes the position of variant Ser and Thr amino acid residues for the
two proteins and color-coded according to variant (red=eEF1A1-specific; blue=eEF1A2-specific). NetPhos-predicted phosphorylation sites are
indicated by a circle, and experimentally determined phosphorylation sites shown with a ‘P’ symbol (these are mapped on the models in
Supplementary file S6).
doi:10.1371/journal.pone.0006315.g004
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yeast-two-hybrid screens are needed.
(b) aminoacyl-tRNA. The placement of aminoacyl-tRNA in
the A site of the ribosome is catalyzed by eEF1A. The equivalent
residues in the human variants of eEF1A that have been proposed
to be part of the aminoacyl-tRNA binding site [38] are Arg322,
His295 and His296, which lie within domain II. These residues
are conserved in both human variants. As mentioned above,
Arg322 is also involved in eEF1Ba–binding, and hence the fact
that Val/Ile320 lies within 5 A ˚ of Arg322 might have a bearing on
aminoacyl-tRNA binding.
(c) GDP/GTP. The co-crystal structures of yeast eEF1A
bound to GDP, GDPnP (a non-hydrolyzable analogue of GTP)
and GDP-Mg
2+ [37,39] provided a detailed picture of the
guanine-binding pocket. This work revealed the critical
importance of Gly19, Lys20, Ser21, Thr22, Asn153, Lys154 and
Asp156 (all in domain I) within the binding sites for these ligands
(Supplementary file S5). These observations were in agreement
with previously performed mutagenesis studies [68] – for example,
the Asn153Thr and Asp156Asn mutations of yeast eEF1A resulted
in dramatic reduction in translational fidelity. Interestingly,
between the unbound eEF1A-eEF1Ba and the eEF1A-eEF1Ba–
GDP/GDPnP bound conformations, Asp156 is reoriented so as to
form H-bonds to the guanine-base [39]. This guanine-binding
pocket is absolutely conserved in both human variants and such an
observation must be reconciled with their differences in GDP/
GTP preference ratios. In this respect it may be relevant that some
variant residues - Gln164Glu, Asn197His and Ala206Pro (eEF1A1
versus eEF1A2 – equivalent to Glu162, Asn195 and Thr204,
respectively, in yeast) lie close to the guanine-binding pocket. Of
particular note is residue 197 that lies immediately adjacent to
Asp156; in the eEF1A1 model, as in the yeast eEF1A structure,
there is a H-bond between the Asn197 (Asn195 in yeast) and
Asp156 side-chains. Such an H-bond cannot exist in eEF1A2 (in
which position 197 is occupied by a His), although it could be
replaced by an ionic interaction. Such a situation in which a key
GDP/GTP contact residue is perturbed could lie behind the
differential guanine binding of the two variants.
(d) Actin. Actin and aminoacyl-tRNA-binding to eEF1A are
mutually exclusive [69]. Previously undertaken mutagenesis
studies in yeast [70,71] identified up to eight residues in eEF1A
clustered within domains II and III, which (i) reduce actin
disorganization induced by overexpression of eEF1A in yeast, (ii)
inhibit actin-bundling without altering translation in vivo, and/or
(iii) reduce actin-bundling. Two such residues implicated in actin-
related functions correspond to variant residues for the human
proteins within sub-cluster 2. Indeed, a site-directed mutation in
yeast eEF1A, Asn329Ser, fortuitously corresponds to changing
eEF1A1 Asn331 to its eEF1A2 equivalent, Ser331. This is one of
two mutations (along with Asn329Asp) that were shown in yeast to
reduce actin-bundling or actin disorganization that is induced by
overexpression of eEF1A [70,71]. Additionally, another equivalent
yeast eEF1A residue that is implicated in actin-related functions is
variable (Met335Gln) between the two human proteins in sub-
cluster 2. Also of note is that yeast eEF1A Phe308 is implicated in
actin-related functions by mutagenesis [71]; the equivalent in
humans (Phe310) contacts Ala326 in eEF1A1 (hydrophobic
interaction) or Cys326 in eEF1A2 (aromatic-sulfur interaction).
In a similar vein, yeast eEF1A Tyr355 is critical for actin-related
functions and the side-chain of its human equivalent (Tyr357) is
adjacent to the side-chain of either Ala358 in eEF1A1 or Ser358 in
eEF1A2. So these differences (Ala326Cys and Ala358Ser) between
Figure 5. Surface properties of the models eEF1A1 and eEF1A2. (A) Two equivalent views, rotated by 180u about the y-axis, of a GRASP-
generated [56] surface electrostatic representation of eEF1A1 (upper panel) and eEF1A2 (lower panel). Negative charge is colored red and positive
charge colored blue, ranging from -10 kT to +10 kT (k=Boltzmann’s constant; T=temperature in Kelvin). Charged residues not present in either
protein (non-conservative charged substitutions only) are labeled – the variant equivalent residue is shown on the right-hand side of the label. (B)
Two equivalent views, rotated by 180u about the y-axis, of a MOLCAD-generated [57] lipophilic surface rendition of the models. Regions of high
lipophilicity or hydrophobicity are colored brown and regions of high hydrophilicity are colored blue.
doi:10.1371/journal.pone.0006315.g005
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critical for actin-related functionality. Previously performed
mutagenesis studies thus serendipitously confirm the importance
of one of the two clusters/binding patches in actin-related
functions; this suggests that the two variants have different actin-
binding and bundling properties consistent with our original
hypothesis. Moreover, this study provides a direction for further
mutagenesis experiments that should target sub-cluster 2 as a
means of understanding the role of the actin-eEF1A interaction.
Homologous (reverse) substitution mutagenesis can
reconcile functional disparities
Our observation of two clusters of variant residues on the
surface of eEF1A1/2 creates the possibility of conducting rational
homologous (reverse) substitution mutagenesis. This is a well-
established approach to delineating precisely which amino acid
residues are responsible for specific functional differences between
highly similar proteins e.g. [72,73]. Thus, the involvement of those
residues predicted to lie within or close to the actin-binding cluster
Asn/Ser331, Met/Gln335, Ala/Cys326 and Ala/Ser358 should
be investigated by this route. Similarly, eEF1A1 mutations
Asn197His (potentially important for GTP/GDP-binding), and
Val320Ile (may be involved in aminoacyl-tRNA-binding and
eEF1Ba-binding) should be probed.
Using the modeled structures to infer differences in
potential sites of phosphorylation
Many of the amino acid differences between the two human
variants involve substitution of Ser or Thr residues (total of 11) and
it is interesting to observe the presence and almost strict
conservation of variant-specific Ser and Thr positions among
orthologues in higher eukaryotes (Figure 4). Four out of the eight
experimentally confirmed phosphorylation sites for the human
variants are not conserved in yeast. A sequence-based NetPhos
phosphorylation analysis of the two variants predicts (.0.5
probability score) five of these eleven sites to be both variant-
specific and potential phosphorylatable. These include Thr217
and Thr227 in eEF1A1; and Ser358, Ser393 and Ser445 in
eEF1A2. The last two residues in eEF1A2 have .0.95 probability
scores [Ser393 (0.99) and Ser445 (0.96)]. When a kinase
encounters a potential substrate for phosphorylation, it recognises
the surface of the protein. From the 3-D models, Thr217, Thr227
(eEF1A1), Ser358 and Ser393 (eEF1A2) all expose their hydroxyl-
groups (Figure 3; Supplementary file S6). Ser445 (eEF1A2) on the
other hand, lies in the C-terminal region that was not modeled; the
equivalent region in the yeast crystal structure was disordered. It is
known that phosphorylation frequently occurs in disordered
regions [74], hence this site too forms another prime candidate
for phosphorylation.
Although overexpression of eEF1A2 has been implicated in a
range of different tumor types, no such role for eEF1A1 has yet
been established. It is tempting to speculate that any difference in
oncogenic potential between the two variants lies in the different
phosphorylation potential of eEF1A1 and eEF1A2. It will thus be
important to confirm phosphorylation of the two most likely
eEF1A2 sites - Ser393 and Ser445 - using, for example, mass
spectrometry. Furthermore, it would be useful to create phos-
phorylation mimics, through mutagenesis of Ser or Thr to Asp or
Glu [75,76], or to a non-phosphorylatable amino acid residue such
as the eEF1A1-equivalent. If Ser393 and Ser445 are indeed
phosphorylated, it would be interesting to raise antibodies to the
phosphorylated forms of eEF1A2 and use these to establish
whether any differences can be seen between eEF1A2 expressed in
tumor compared to normal tissue. Such studies would not only
yield biological insights but could also provide useful diagnostic
reagents.
Conclusions
We set out to use homology modeling to address two
hypotheses: first, amino acid differences between the two variants
dictate differences in relative binding affinities or specificities for
aminoacyl-tRNA and/or actin, reflecting differential roles in
various cell types; second, differential phosphorylation of the two
variants effectively amplifies their chemical differences and
promotes functional divergence. The 3-D models reveal two
distinct sub-clusters of sequence variation on one face of the
proteins. We observed that variable amino acid residues within
one of these clusters overlapped with residues implicated in actin-
bundling and disorganization. Some other variable residues
participate in interactions with, or lie in close proximity to, amino
acid residues directly involved in binding GTP/GDP, eEF1Ba and
aminoacyl-tRNA. These findings are in predictive agreement with
our first hypothesis and identify, high-priority targets for rational
site-directed mutagenesis including homologous reverse substitu-
tion experiments. In addition the models, in support of our second
hypothesis, suggest possible differences of phosphorylation and
hence future experiments to investigate differences in phosphor-
ylation between the variants.
Supporting Information
File S1 Yeast crystal structure comparison. (A) Table depicting
the six different yeast eEF1A crystal structures in the Protein Data
Bank (PDB) [4], resolution, PDB chains and solved residue
lengths, along with each of their corresponding interacting
eEF1Ba proteins and ligands. (B) MultiProt [5,6] structural
superposition of all six eEF1A crystal structures highlights the
structural conservation among them. Each structure color-coded
differently. (C) Table depicting the pair-wise structural compar-
isons for all vs. all yeast crystal structures. The Combinatorial
Extension [7] calculated Ca root mean square deviation (RMSD)
is shown in Angstroms along with the structural alignment length
between the two proteins. The closeness of the structures is evident
in this table.
Found at: doi:10.1371/journal.pone.0006315.s001 (0.13 MB
PDF)
File S2 Ramachandran evaluation plots for models of human
eEF1A1 and eEF1A2. Top: Ramachandran plot scores for
eEF1A1: most favored regions: 93.6%; additional allowed regions:
5.1%; generously allowed regions: 1.1%; disallowed regions: 0.3%.
Bottom: Ramachandran plot scores for eEF1A2: most favored
regions: 92%; additional allowed regions: 6.7%; generously
allowed regions: 1.3%; disallowed regions: 0%. Ideally, one would
hope to have.90% residues in the ‘‘most favored’’ regions of the
Ramachandran plot [1,2].
Found at: doi:10.1371/journal.pone.0006315.s002 (0.09 MB
PDF)
File S3 3-D model co-ordinates of human eEF1A1 and eEF1A2.
Note: co-ordinates for both models (human eEF1A1 and human
eEF1A2) are provided in one PDB file.
Found at: doi:10.1371/journal.pone.0006315.s003 (1.13 MB
TXT)
File S4 Sequence alignment between archaeal EF1A (Sulfolobus
solfataricus) and yeast (Saccharomyces cerevisiae) eEF1A. Pair-wise
sequence alignment between eEF1A from yeast vs. EF1A from
archaea. From the structures of yeast and archaea, residues
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yeast amino acid residue involved in domain-domain contact,
when bound to eEF1Ba; & = archaea amino acid residue
involved in domain-domain contact, free of eEF1Ba; underlined
residues = not present in the crystal structures. Identical positions
in the alignment are shown with a yellow background; variable
positions involved in a domain-domain contact are highlighted
with a red background. A total of 42 residues are involved in
domain-domain contacts in the eEF1Ba-bound yeast structure, 17
are non-identical at the equivalent position in the archaeal
sequence, and conversely, there are 40 residues involved in
domain-domain contacts within the unbound archaeal structure,
14 of which are non-identical in the yeast sequence.
Found at: doi:10.1371/journal.pone.0006315.s004 (0.08 MB
PDF)
File S5 Guanine-binding pocket in yeast and human variants.
Close-up equivalent views of residues involved in binding of GTP/
GDP: the yeast template (top left); all six yeast eEF1A structures
superposed (top right) and colored differently (see their corre-
sponding PDB IDs below); human eEF1A1 (bottom left); and
human eEF1A2 (bottom right). Labeled residues include: Gly19,
Lys20, Ser21, Thr22, Asn153, Lys154, Asp156 [GTP/GDP-
binding residues] and Asn195 (yeast), Asn/His197 (human
eEF1A1/eEF1A2) that show presence of H-bond (indicated by a
yellow dashed line and distance in Angstroms) with Asp156, absent
in human eEF1A2. Atomic color scheme for yeast template and
human variants: nitrogen: blue; oxygen: red; carbon: yellow (note:
for clarity hydrogen atoms not shown).
Found at: doi:10.1371/journal.pone.0006315.s005 (0.15 MB
PDF)
File S6 Location of known and variable potential phosphor-
ylatable residues on eEF1A1 and eEF1A2 models. Cartoon
schematic representation of the 3-D models of eEF1A1 and
eEF1A2 depicting the location of the known (orange) and potential
(green) phospho-Ser, -Thr and -Tyr residues (side-chain shown in
stick representation without hydrogen atoms, for clarity). Poten-
tially phosphorylated Ser445 in eEF1A2 is located in a disordered
region, and is hence not seen in the figure. Note: all experimentally
confirmed phosphorylation sites are conserved between the human
variants, and have not been unambiguously determined specifi-
cally to each or both variants. For purposes of the figure,
phosphorylated residues are depicted on the models as reported in
the PhosphoSitePlus database (http://www.phosphosite.org) [1]:
for eEF1A1 (Tyr29, Tyr85, Tyr86, Tyr141, Tyr162, Ser163, and
Thr432); and for eEF1A2 (Tyr29, Tyr141, and Tyr254).
Found at: doi:10.1371/journal.pone.0006315.s006 (0.54 MB
PDF)
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